Journal of Neurology

, Volume 258, Issue 11, pp 2048–2053 | Cite as

Gender effect on time to levodopa-induced dyskinesias

  • Sharon Hassin-Baer
  • Irena Molchadski
  • Oren S. Cohen
  • Zeev Nitzan
  • Lilach Efrati
  • Olga Tunkel
  • Evgenia Kozlova
  • Amos D. Korczyn
Original Communication

Abstract

Levodopa-induced dyskinesias (LID) are commonly observed during long-term treatment of patients with Parkinson’s disease (PD). The impact of non-pharmacological factors on the latency to LID appearance is not known. The aim of the paper was to identify factors associated with time to appearance of LID. Consecutive PD patients treated with levodopa (n = 155) were included in this historical prospective analysis and LID and non-LID groups were compared. The relationship between possible risk factors and the time of LID onset was explored using the Kaplan–Meier method and the Cox multivariate regression model, controlling for the confounding effects of gender, age of disease onset, time to initiation of levodopa treatment, and history of smoking. Patients with LID (57.4%) were significantly younger at disease onset and had a slightly longer latency from diagnosis to levodopa treatment than those without; disease duration and age had no effect on LID appearance. Female gender was associated with a shorter time to LID and the median time to LID was 6 years for males and 4 years for females (p = 0.004). In the multivariate survival analysis a younger age of onset of PD and a longer time from diagnosis to levodopa treatment initiation were also associated with a shorter time to LID appearance (p = 0.030 and 0.036, respectively). Female gender is associated with a significantly shorter latency to LID appearance. Younger age at PD diagnosis and a longer time until starting levodopa are associated with both higher likelihood to develop LID, and a shorter latency until LID were observed.

Keywords

Parkinson’s disease Levodopa Levodopa-induced dyskinesias Gender Smoking Age of onset Risk factors 

References

  1. 1.
    Samii A, Nutt JG, Ransom BR (2004) Parkinson’s disease. Lancet 363:1783–1794PubMedCrossRefGoogle Scholar
  2. 2.
    Korczyn AD (1972) Pathophysiology of drug-induced dyskinesias. Neuropharmacology 11:601–607PubMedCrossRefGoogle Scholar
  3. 3.
    Thanvi B, Lo N, Robinson T (2007) Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 83(980):384–388PubMedCrossRefGoogle Scholar
  4. 4.
    Duvoisin RC (1974) Hyperkinetic responses with L-DOPA. In: Yahr MD (ed) Current concepts in the treatment of parkinsonism. Raven Press, New York, pp 203–210Google Scholar
  5. 5.
    Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16(3):448–458PubMedCrossRefGoogle Scholar
  6. 6.
    Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann Neurol 39:37–45CrossRefGoogle Scholar
  7. 7.
    Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 342(20):1484–1491PubMedCrossRefGoogle Scholar
  8. 8.
    Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson’s disease: a community-based study. Brain 123:2297–2305PubMedCrossRefGoogle Scholar
  9. 9.
    Grandas F, Galiano ML, Tabernero C (1999) Risk factors for levodopa-induced dyskinesias in Parkinson’s disease. J Neurol 246:1127–1133PubMedCrossRefGoogle Scholar
  10. 10.
    Van Gerpen JA, Kumar N, Bower JH et al (2006) Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976–1990. Arch Neurol 63:205–209PubMedCrossRefGoogle Scholar
  11. 11.
    Hauser RA, McDermott MP, Messing S (2006) Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 63(12):1756–1760PubMedCrossRefGoogle Scholar
  12. 12.
    Ku S, Glass GA (2010) Age of Parkinson’s disease onset as a predictor for the development of dyskinesia. Mov Disord 25(9):1177–1182PubMedCrossRefGoogle Scholar
  13. 13.
    Fahn S, the Parkinson Study Group (2005) Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol 252:IV37–IV42PubMedCrossRefGoogle Scholar
  14. 14.
    Lyons KE, Hubble JP, Tröster AI et al (1998) Gender differences in Parkinson’s disease. Clinical Neuropharmacol 21(2):118–121Google Scholar
  15. 15.
    Zappia M, Annesi G, Nicoletti G et al (2005) Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol 62(4):601–605PubMedCrossRefGoogle Scholar
  16. 16.
    Sharma JC, Macnamara L, Hasoon M, Vassallo M, Ross I (2006) Cascade of levodopa dose and weight-related dyskinesia in Parkinson’s disease (LD-WD-PD cascade). Parkinsonism Relat Disord 12:499–505PubMedCrossRefGoogle Scholar
  17. 17.
    Strong JA, Dalvi A, Revilla FJ et al (2006) Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord 21(5):654–659PubMedCrossRefGoogle Scholar
  18. 18.
    Oliveri RL, Annesi G, Zappia M et al (1999) Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology 53:1425PubMedGoogle Scholar
  19. 19.
    Kaiser R, Hofer A, Grapengiesser A, Gasser T, Kupsch A, Roots I, Brockmöller J (2003) L-dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology 60:1750–1755PubMedGoogle Scholar
  20. 20.
    Watanabe M, Harada S, Nakamura T, Ohkoshi N, Yoshizawa K, Hayashi A, Shoji S (2003) Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson’s disease. Neuropsychobiology 48(4):190–193PubMedCrossRefGoogle Scholar
  21. 21.
    Molchadski I, Korczyn AD, Cohen OS, Katzav A, Nitzan Z, Chapman J, Hassin-Baer S (2011) The role of Apolipoprotein E polymorphisms in the development of levodopa-induced dyskinesia. Acta Neurol 123(2):117–121Google Scholar
  22. 22.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184PubMedCrossRefGoogle Scholar
  23. 23.
    Kandinov B, Giladi N, Korczyn AD (2009) Smoking and tea consumption delay onset of Parkinson’s disease. Parkinsonism Relat Disord 15(1):41–46PubMedCrossRefGoogle Scholar
  24. 24.
    Kandinov B, Giladi N, Korczyn AD (2007) The effect of cigarette smoking, tea and coffee consumption on the progression of Parkinson’s disease. Parkinsonism Relat Disord 13(4):243–245PubMedCrossRefGoogle Scholar
  25. 25.
    Sharma JC, Bachmann CG, Linazasoro G (2010) Classifying risk factors for dyskinesia in Parkinson’s disease. Parkinsonism Relat Disord 16(8):490–497PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Sharon Hassin-Baer
    • 1
    • 3
  • Irena Molchadski
    • 1
    • 3
  • Oren S. Cohen
    • 1
    • 3
  • Zeev Nitzan
    • 1
    • 3
  • Lilach Efrati
    • 1
  • Olga Tunkel
    • 1
  • Evgenia Kozlova
    • 1
  • Amos D. Korczyn
    • 2
    • 3
  1. 1.Department of Neurology, Parkinson and Movement Disorders Clinic, Sagol Neuroscience CenterChaim Sheba Medical CenterRamat-GanIsrael
  2. 2.Sieratzki Chair of NeurologyTel Aviv UniversityTel-AvivIsrael
  3. 3.Sackler School of MedicineTel Aviv UniversityTel-AvivIsrael

Personalised recommendations